There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Relay Therapeutics (RLAY – Research Report) and Kura Oncology (KURA – Research Report) with bullish sentiments.
Relay Therapeutics (RLAY)
JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Relay Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $7.04.
According to TipRanks.com, Tuerkcan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Relay Therapeutics with a $22.43 average price target, representing a 157.5% upside. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $25.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Kura Oncology (KURA)
JMP Securities analyst Reni Benjamin maintained a Buy rating on Kura Oncology today and set a price target of $32.00. The company’s shares closed last Friday at $20.63.
According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Kura Oncology is a Strong Buy with an average price target of $31.09, which is a 51.3% upside from current levels. In a report issued on May 3, Barclays also maintained a Buy rating on the stock with a $32.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RLAY:
- Relay Therapeutics reports Q1 EPS (62c), consensus (71c)
- Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
- Relay Therapeutics to Participate in Upcoming Investor Conferences
